Kanada - anglų - Health Canada

aptevo biotherapeutics llc - anti-d (rh) immunoglobulin (human) - kit - 5000unit - anti-d (rh) immunoglobulin (human) 5000unit - serums

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabbit antithymocyte immunoglobulin, quantity: 25 mg - injection, powder for - excipient ingredients: sodium chloride; glycine; mannitol - thymoglobuline (rabbit anti-human thymocyte immunoglobulin) is indicated for the prophylaxis of graft rejection in renal transplantation; treatment of steroid-resistant or moderate to severe renal transplant rejection: and treatment of refractory or relapsing aplastic anaemia.

Izraelis - anglų - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - solution for injection - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.

Kanada - anglų - Health Canada

cutter med & biol, division of miles canada ltd. - human immunoglobulins (anti-d (rh) immunoglobulin (human)) - liquid - 16.5% - human immunoglobulins (anti-d (rh) immunoglobulin (human)) 16.5% - serums

Kanada - anglų - Health Canada

rh pharmaceuticals inc. - sodium chloride; anti-d (rh) immunoglobulin (human) - kit - 0.9%; 120mcg - sodium chloride 0.9%; anti-d (rh) immunoglobulin (human) 120mcg - serums

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) - solution for injection - 160 mg/ml - active: immunoglobulin g 160 mg/ml (immunoglobulin ex nz 16% igg) excipient: glycine - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - anti-d rho immunoglobulin,human immunoglobulin g -

Izraelis - anglų - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - solution for injection - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - anti-d [rho] immunoglobulin 625 iu/ml; plasma protein fraction 165 mg/ml (human) - solution for injection - 1250 iu - active: anti-d [rho] immunoglobulin 625 iu/ml plasma protein fraction 165 mg/ml (human) excipient: glycine immunoglobulin a. not less than or equal to.05% of total protein polysorbate 80 sodium tributyl phosphate water for injection - · prevention of rh(d) immunisation in rh(d) negative women. - pregnancy/delivery of a rh-positive baby. - abortion/threatened abortion, ectopic pregnancy or hydatidiform mole. - transplacental haemorrhage (tph) resulting from ante-partum haemorrhage (aph), amniocentesis, chorionic biopsy or obstetric manipulative procedures, e.g. external version, or abdominal trauma. · treatment of rh(d) negative persons after incompatible transfusions of rh(d) positive blood or other products containing red blood cells.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - anti-d [rho] immunoglobulin 625 iu/ml; plasma protein fraction 165 mg/ml (human) - solution for injection - 625 iu/ml - active: anti-d [rho] immunoglobulin 625 iu/ml plasma protein fraction 165 mg/ml (human) excipient: glycine immunoglobulin a polysorbate 80 sodium tributyl phosphate water for injection - · prevention of rh(d) immunisation in rh(d) negative women. - pregnancy/delivery of a rh-positive baby. - abortion/threatened abortion, ectopic pregnancy or hydatidiform mole. - transplacental haemorrhage (tph) resulting from ante-partum haemorrhage (aph), amniocentesis, chorionic biopsy or obstetric manipulative procedures, e.g. external version, or abdominal trauma. · treatment of rh(d) negative persons after incompatible transfusions of rh(d) positive blood or other products containing red blood cells.